Category: Latest News

Download the official ASX announcement HERE: https://www.asx.com.au/asxpdf/20190724/pdf/446v0xxd73w4sr.pdf Bluechiip Limited (Bluechiip or the Company) (ASX: BCT) today released its quarterly cash flow report for the quarter ended 30 June 2019. ACTIVITIES REPORT FOR THE QUARTER ENDED 30 JUNE 2019 Business highlights A record quarter with net sales revenue of $517k (unaudited) from the delivery of readers,…

You can download the original announcement HERE: https://www.asx.com.au/asxpdf/20190724/pdf/446v120vjdzp8z.pdf In this Open Briefing®, Andrew discusses: Quarterly cash results for quarter ended 30 June2019 Growth in the installed reader base, enabling growth in use of Bluechiip technology and consumables Expected step up increase in cash receipts in the coming quarters and ongoing sales growth Additional OEM proposals…

The piece of news of an IVF mix-up has made it around the world. A Woman unwittingly received 2 eggs from 2 different donors and needs to return newborns to their biologic parents. “According to the lawsuit, the couple do not know what happened to their own two embryos, which they believe “were never thawed…

This May at the ISBER annual meeting, the team lead by Cristina Villena from the Pulmonary Biobank Platform (PBP) in Son Espases Hospital, Spain presented a poster about enhancing productivity in biobanking operations. The Bluechiip Sample Management System (under the “MEMS” technology denomination) showed a significant increase in productivity over traditional 1D labels and 2D…

Clieck HERE to read our latest Open Briefing interview with Andrew McLellan https://www.asx.com.au/asxpdf/20190429/pdf/444lr6fnh6n4gh.pdf

You will always find the latest presentation and videos under the Company Overview page Download the March 2019 Broker Presentation Watch the Corpoporate Video updated this week: 26th of March 2019

In this Open Briefing®, Andrew discusses: • Four new OEM proposals under consideration • Growing market enquiries and successful trade shows including ISBER and SLAS • Six months trading results, period ended 31 December 2018 • Changing revenue mix to ongoing consumables sales • Increasing production and delivery under US$11.9m Labcon contract Open Briefing interview…

The “Pulmonary Biobank Consortium, CIBER of Respiratory Diseases (CIBERES) – ISCIII (Madrid), Institut d’Investigació Sanitària de les Illes Balears (IdISBA) – Hospital Universitari Son Espases, Mallorca, Spanish Biobank Network” recently presented a scientific poster about Bluechiip technology in the International Society of Biobanks and Environmental Repositories (ISBER) Symposium this February 2019 in Berlin. See CIBERES…

In this Open Briefing, Andrew discusses: Labcon’s official release and marketing of Bluechiip enabled product Accelerating sales and production scaling progress Reader production status and approvals Partner progress and cash position Download the full document here: https://www.asx.com.au/asxpdf/20190130/pdf/4425m31s7m9cnn.pdf

Download the presentation shown during the past AGM on the 26th of November 2018 https://www.asx.com.au/asxpdf/20181126/pdf/440mb0vpc9v670.pdf